Ellume Recall, page-22

Maybe that secret sauce is no longer part of the deal.
Would it be the first time that the successful partners ditches the supplier?

BBI comes to mind, abusing Anteo for ideas during tech exchange period to then go it alone.
The very fact that we have STILL not heard of an Ellume follow up contract was already a red flag 2 months ago.
Paired with the very low revenue from that contract until the prospective early 2022 would
enable Ellume to find alternative ways to do business.

To illuminate the approach, look not further than to Biontech and Pfizer.
Pfizer had their inhouse scientists crack the code on several fronts to implement the
ground work of the German based Biontech partner to expand into mRNA platforms outside the vaccine they had partned with Biontech for.

Pfizer scientists are now enabled to multiply the ground work financially played by a partner.

Anteo starts to look that way increasingly, hence the permanent feature of being late to the party.


all IMO